Dr. Roche joins HTG from Ventana Medical Systems/Roche Tissue Diagnostics where he served as Vice President of Translational Diagnostics and was responsible for interfacing with pharmaceutical partners in their development of targeted cancer therapeutics and facilitating the transition of biomarkers into companion diagnostics.Dr. Roche also led reagent product development at Ventana, launching over thirty in vitro diagnostic (IVD) products, including the FDA-approved c-kit and HER2 tests. Prior to his time at Ventana, Dr. Roche served as Director of the Immunohistochemistry Laboratory and Associate Professor of Pathology and Biochemistry-Molecular Biology for Mayo Clinic Rochester.Dr. Roche has co-authored more than 125 peer-reviewed publications.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
HTG Molecular Diagnostics | HTG Molecular Diagnostics | Apr 1, 2014 | — | Detail |